The abstract is read at the publisher; the summary is JClub's.
Atorvastatin promotes bone anabolism under estrogen-deficient conditions by driving osteogenic differentiation of LEPR+ bone marrow stromal cells, including skeletal stem/progenitor cells.
- Why it matters: Menopause-linked estrogen deficiency contributes to age-related bone loss, and it is unclear whether statins act differently when estradiol signaling is reduced.
- What they did: In postmenopausal women, statin use is linked to a slower annual decline in bone mineral density, and in estrogen-deficient models atorvastatin induces osteoblast formation via RAC1 prenylation restriction and NF-κB–mediated Oln transcription in LEPR+ cells.
- The result: The data suggest statins can compensate for reduced estradiol–estrogen receptor-α signaling through a mechanistically distinct osteogenic pathway, repositioning estrogen action to earlier stem/progenitor differentiation stages.
The findingWhy it mattersWhat they didThe result
AI summary of the abstract · may contain errors · not medical advice · read the paper.